MORE women with breast cancer could be spared chemotherapy if doctors switched to a new genetic test, research shows.
“EPclin (EndoPredict) Markedly Outperformed RS (Oncotype DX®) Across the 10-Year Follow-up Period” in a Large Head-to-Head Breast Cancer Study
Feb 11, 2016 | a GenomeWeb staff reporter
NEW YORK (GenomeWeb) – More young women with breast cancer are undergoing BRCA1 and BRCA2 mutation testing, according to a Dana-Farber Cancer Institute-led team of researchers.
Run For Hope is an annual run that aims to raise much-needed awareness and support for cancer research. For their 23rd year running, SciencewerkeDx was privileged to be a part of Run For Hope 2016 as a Gold Sponsor.
SAN ANTONIO, TX—EndoPredict (EP) provides more prognostic information than the Oncotype DX recurrence score (RS) for distant recurrence (DR) in overall, N+, and N– patient populations, with the greatest differences between EPclin and RS in patients who were N+. In addition, EPclin identified a group of patients at low risk who may be spared chemotherapy.